| scholarly article | Q13442814 |
| P50 | author | Maura H Parker | Q125344957 |
| Rainer Storb | Q19546769 | ||
| P2093 | author name string | Scott S Graves | |
| P2860 | cites work | Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates | Q44557802 |
| Fractionated total body irradiation and autologous bone marrow transplantation in dogs: hemopoietic recovery after various marrow cell doses. | Q44850685 | ||
| Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. | Q45050218 | ||
| Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. | Q45869798 | ||
| Isolation and characterization of pediatric canine bone marrow CD34+ cells | Q45876694 | ||
| CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. | Q45984095 | ||
| Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. | Q47104749 | ||
| Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity | Q47178151 | ||
| Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease | Q47586153 | ||
| Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations | Q47605536 | ||
| Lymphocyte typing in allografted beagles | Q47805701 | ||
| Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing | Q47808575 | ||
| Cytotoxic typing antisera for marrow grafting in littermate dogs | Q47816843 | ||
| Molecular analysis and polymorphism of the DLA-DQB genes | Q48010732 | ||
| Hematopoietic-cell transplantation at 50. | Q48546980 | ||
| In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. | Q48680865 | ||
| Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease | Q49662013 | ||
| Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial | Q50040577 | ||
| Revamp animal research rules, report urges | Q50092299 | ||
| Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). | Q50782599 | ||
| TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice. | Q52014017 | ||
| Failure of allogeneic canine marrow grafts after total-body irradiation. Allogeneic "resistance" versus transfusion-induced sensitization. | Q52136176 | ||
| Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. | Q52905842 | ||
| Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. | Q53619773 | ||
| Marrow Infusions in Dogs Given Midlethal or Lethal Irradiation | Q53759962 | ||
| A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. | Q53975414 | ||
| Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
| Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. | Q55510169 | ||
| JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs | Q56900336 | ||
| Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model | Q56906237 | ||
| Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study | Q78385763 | ||
| [Trial therapy, by x-irradiation followed by the administration of homologous bone marrow cells, of highly-advanced spontaneous leukemia in AK mice.] | Q78467291 | ||
| Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation | Q78494858 | ||
| Pathological changes in F1 hybrid mice following transplantation of spleen cells from donors of the parental strains | Q78651273 | ||
| Value of bone marrow and spleen cell suspensions for survival of lethally irradiated dogs | Q79280034 | ||
| Marrow transplants in lethally irradiated dogs given methotrexate | Q79428981 | ||
| Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma | Q80313398 | ||
| CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma | Q80352090 | ||
| An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201 | Q80456836 | ||
| Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation | Q81506471 | ||
| Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial | Q81793164 | ||
| Sudden loss of the GVL effect following use of the TNF inhibitor infliximab in a chronic myelogenous leukemia patient with chronic GVHD | Q84700524 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report | Q89700420 | ||
| Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial | Q34446176 | ||
| Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes | Q34581469 | ||
| Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation | Q34683729 | ||
| A compendium of reported human bone marrow transplants | Q34700669 | ||
| Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice | Q35092307 | ||
| Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells | Q35227334 | ||
| Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation | Q35234495 | ||
| Anti-CD28 Antibody-Initiated Cytokine Storm in Canines | Q35610659 | ||
| Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy | Q35752854 | ||
| Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans | Q35776453 | ||
| Characterization of target injury of murine acute graft-versus-host disease directed to multiple minor histocompatibility antigens elicited by either CD4+ or CD8+ effector cells | Q35830507 | ||
| Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation | Q35848787 | ||
| Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes | Q35885125 | ||
| Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation | Q36113141 | ||
| Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A | Q36347506 | ||
| Transplant tolerance in non-human primates: progress, current challenges and unmet needs | Q36447590 | ||
| Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment | Q36488985 | ||
| Murine models of chronic graft-versus-host disease: insights and unresolved issues | Q36645730 | ||
| Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice | Q36718005 | ||
| Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation | Q36763834 | ||
| Molecular analysis and polymorphism of the DLA-DQA gene | Q36830133 | ||
| Molecular analysis of the DLA DR region | Q36841269 | ||
| Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment | Q36861714 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 | ||
| Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target | Q36966278 | ||
| Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future | Q36980277 | ||
| Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism | Q37016470 | ||
| Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? | Q37035815 | ||
| Mouse models of bone marrow transplantation | Q37045969 | ||
| Graft failure after allogeneic hematopoietic cell transplantation | Q37045988 | ||
| Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect | Q37095317 | ||
| Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes | Q37143633 | ||
| Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. | Q37275902 | ||
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice | Q24288997 | ||
| Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation | Q24626051 | ||
| Nonmyeloablative allogeneic hematopoietic cell transplantation | Q26748780 | ||
| Immuno-intervention for the induction of transplantation tolerance through mixed chimerism | Q27001243 | ||
| Radioimmunotherapy of human tumours | Q28088825 | ||
| The canine genome | Q28285982 | ||
| Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma | Q28299569 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer | Q29619483 | ||
| Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials | Q30997153 | ||
| Organization of the canine major histocompatibility complex: current perspectives | Q31905980 | ||
| Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation | Q33388983 | ||
| Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation | Q33398529 | ||
| Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial | Q33411822 | ||
| Identification of MHC II-Restricted Minor Histocompatibility Antigens After HLA-Identical Stem-Cell Transplantation | Q33677067 | ||
| IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. | Q33853636 | ||
| Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia | Q33857573 | ||
| NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects | Q33887452 | ||
| Insights into morphology and disease from the dog genome project | Q33904330 | ||
| Spontaneously occurring tumors of companion animals as models for human cancer | Q33927360 | ||
| A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease | Q33964687 | ||
| Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy | Q33969561 | ||
| Large animal models of hematopoietic stem cell gene therapy | Q34039922 | ||
| Supralethal whole body irradiation and isologous marrow transplantation in man. | Q34250866 | ||
| An MHC-Defined Primate Model Reveals Significant Rejection of Bone Marrow After Mixed Chimerism Induction Despite Full MHC Matching | Q34307416 | ||
| Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis | Q34337007 | ||
| A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease | Q59065980 | ||
| Pharmacologic, toxicologic, and marrow transplantation studies in dogs given succinyl acetone | Q67585400 | ||
| Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marro | Q67741731 | ||
| Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease | Q67903035 | ||
| Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow | Q68242113 | ||
| Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts | Q68743119 | ||
| Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease | Q68882743 | ||
| Marrow grafts between histoincompatible canine family members | Q69233061 | ||
| Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs | Q69273159 | ||
| Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran | Q69365561 | ||
| Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation | Q69506136 | ||
| Autologous bone marrow grafts in dogs treated with lethal doses of cyclophosphamide | Q69873751 | ||
| Allogeneic canine bone marrow transplantation following cyclophosphamide | Q69876471 | ||
| The repopulation of irradiated bone marrow by the infusion of stored autologous marrow | Q69897397 | ||
| Transplantation of stored allogeneic bone marrow in dogs selected by histocompatibility typing | Q69907310 | ||
| Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation | Q69912101 | ||
| Radioimmunotherapy with alpha-particle-emitting immunoconjugates | Q69918183 | ||
| Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
| Cyclosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs | Q70172378 | ||
| High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival | Q70192594 | ||
| What radiation dose for DLA-identical canine marrow grafts? | Q70213348 | ||
| Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates | Q70318454 | ||
| Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell | Q71142561 | ||
| Adoptive immunotherapy of acute leukemia: experimental and clinical results | Q71170609 | ||
| Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation | Q71299277 | ||
| Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance | Q71442356 | ||
| A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease | Q71588928 | ||
| FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors | Q72100042 | ||
| Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation | Q73235565 | ||
| Prevention of irradiation-induced lymphoid tumors in C57BL mice by spleen protection | Q73298607 | ||
| Humoral factor in irradiation protection: modification of lethal irradiation injury in mice by injection of rat bone marrow | Q73384569 | ||
| Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation | Q73398048 | ||
| Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers | Q73427004 | ||
| The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse | Q73533291 | ||
| Effects of non-major histocompatibility antigens on acute graft-versus-host reaction after allogeneic bone marrow transplantation | Q73670153 | ||
| Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow | Q73726902 | ||
| Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation | Q73783372 | ||
| Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia | Q73784852 | ||
| Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model | Q73828922 | ||
| Mortality and skin transplantability in x-irradiated mice receiving isologous, homologous or heterologous bone marrow | Q74268409 | ||
| Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts | Q74357436 | ||
| Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial | Q74389035 | ||
| Treatment of murine leukaemia with x-rays and homologous bone marrow. II | Q74602320 | ||
| Modification of irradiation injury in mice and guinea pigs by bone marrow injections | Q75832754 | ||
| Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease | Q77136941 | ||
| Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation | Q78039826 | ||
| Comparing high and low total body irradiation dose rates for minimum-intensity conditioning of dogs for dog leukocyte antigen-identical bone marrow grafts | Q37287517 | ||
| Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model | Q37357517 | ||
| Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. | Q37387081 | ||
| Pathophysiology of GvHD and Other HSCT-Related Major Complications | Q37710572 | ||
| Mouse models of graft-versus-host disease: advances and limitations | Q37874011 | ||
| A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. | Q38096524 | ||
| Advances in the development of animal models of myeloid leukemias | Q38161668 | ||
| Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice | Q38163336 | ||
| Preclinical modeling of hematopoietic stem cell transplantation - advantages and limitations | Q38660463 | ||
| How important is histocompatibility in bone marrow transplantation? | Q38687869 | ||
| Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. | Q38758789 | ||
| A Canine Model of Chronic Graft-versus-Host Disease | Q38778387 | ||
| Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes | Q38852431 | ||
| Canine allogeneic bone marrow transplantation. Technique and variables influencing engraftment | Q39114914 | ||
| Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum | Q39170481 | ||
| Graft-versus-host disease in dog and man: the Seattle experience | Q39839309 | ||
| Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). | Q39933579 | ||
| Effects of HOXB4 overexpression on ex vivo expansion and immortalization of hematopoietic cells from different species | Q40131427 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques | Q40584637 | ||
| Prevention and treatment of relapse by bone marrow transplantation. | Q40723052 | ||
| Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease | Q40831481 | ||
| Treatment of severe aplastic anemia using antithymocyte globulin with or without an infusion of HLA haploidentical marrow. | Q40851391 | ||
| Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model | Q40950055 | ||
| Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease | Q40991233 | ||
| Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions | Q41116466 | ||
| Dose rate and dose fractionation studies in total body irradiation of dogs | Q41122502 | ||
| Total body irradiation and autologous marrow transplantation as consolidation therapy for spontaneous canine lymphoma in remission | Q41210282 | ||
| Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions | Q41210500 | ||
| The CD28-B7 costimulatory pathway and its role in autoimmune disease. | Q41567048 | ||
| AN ASSAY OF GRAFT-HOST INTERACTIONS ACROSS STRONG AND WEAK HISTOCOMPATIBILITY BARRIERS IN MICE | Q41966133 | ||
| Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia | Q42824835 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| T-cell depletion of HLA-identical transplants in leukemia. | Q43844182 | ||
| Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
| Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation | Q44333081 | ||
| IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs | Q44458201 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 263-275 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | ILAR Journal | Q15756706 |
| P1476 | title | Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation | |
| P478 | volume | 59 |
| Q99566339 | Induction of Tolerance Towards Solid Organ Allografts Using Hematopoietic Cell Transplantation in Large Animal Models | cites work | P2860 |
Search more.